Treatment with inhaled mometasone furoate reduces short-acting β2 agonist claims and increases adherence compared to fluticasone propionate in asthma patients

Value in Health

Volumn 14, Issue 2, 2011, Pages 339-346

  Navaratnam, Prakash ^a   Friedman, Howard S ^b   Urdaneta, Eduardo ^c  

^a Eympres Research   (United States)

^b Analytic Solutions LLC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adherence; Asthma; Fluticasone propionate; Mometasone furoate

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEVALBUTEROL; MOMETASONE FUROATE; PROCATEROL; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DISEASE EXACERBATION; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 79959588638     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.01.001     Document Type: Article

References (33)

1. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report. 2007. Available from: Http://www.nhlbi.nih.gov/guidelines/asthma/asthupdt.htm. [Accessed March 4,2009]
2. Donohue JF. Safety and efficacy of beta agonists. Respir Care 2008;53:618-22; discussion 23-4.
3. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
4. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109:57-62. (Pubitemid 34112130)
5. Lieu TA, Quesenberry CP, Sorel ME, et al. Computer-based models to identify high-risk children with asthma. Am J Respir Crit Care Med 1998;157:1173-80.
6. Schatz M, Nakahiro R, Crawford W, et al. Asthma quality-of-care markers using administrative data. Chest 2005;128:1968-73. (Pubitemid 41507529)
7. Food and Drug Administration. Use of ozone-depleting substances; removal of essential-use designations; final rule. Fed Regist 2005;70:17168-92.
8. Harnest U, Price D, Howes T, Sussman G. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: Findings from a noninferiority trial. J Asthma 2008;45:215-20. (Pubitemid 351549800)
9. Wardlaw A, Larivee P, Eller J, et al. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004;93:49-55. (Pubitemid 39243135)
10. Asmanex® Twisthaler®. Mometasone furoate inhalation powder package insert. Kenilworth, NJ: Schering Corporation, 2008.
11. Flovent® HFA (fluticasone propionate inhalation aerosol) Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline, 2007.
12. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310. (Pubitemid 32804122)
13. Guest JF, Davie AM, Ruiz FJ, Greener MJ. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005;14:88-98. (Pubitemid 40410057)
14. Horne R. Compliance, adherence, and concordance: Implications for asthma treatment. Chest 2006;130(Suppl. 1):65S-72S. (Pubitemid 44107237)
15. Friedman HS, Yawn BP. Resource utilization in asthma: Combined fluticasone propionate/salmeterol compared with inhaled corticosteroids. Curr Med Res Opin 2007;23:427-34. (Pubitemid 46333390)
16. Black P. Greedy algorithm, in Dictionary of Algorithms and Data Structures; U.S. National Institute of Standards and Technology. Feb 2, 2005. Available from: Http://www.itl. nist.gov/div897/sqg/dads/HTML/greedyalgo.html. [Accessed March 4, 2009].
17. Allen-Ramey FC, Bukstein D, Luskin A, et al. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. J Manag Care Pharm 2006;12:310-21. (Pubitemid 47394446)
18. Drugs for asthma. Treat Guidel Med Lett 2008;6:83-90.
19. Schatz M, Zeiger RS, Vollmer WM, et al. Determinants of future long-term asthma control. J Allergy Clin Immunol 2006;118:1048-53. (Pubitemid 44666992)
20. Bateman ED, Boushey HA, Bousquet J, et al. Can guidelinedefined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170: 836-44. (Pubitemid 39346477)
21. Paris J, Peterson EL, Wells K, et al. Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol 2008;101:482-7.
22. Gillissen A. Patients' adherence in asthma. J Physiol Pharmacol 2007;58(Suppl 5):205-22. (Pubitemid 351346668)
23. Krishnan JA, Riekert KA, McCoy JV, et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med 2004;170:1281-5. (Pubitemid 39657191)
24. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: Responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am 2005; 25:107-30. (Pubitemid 39576680)
25. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4. (Pubitemid 20316533)
26. Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005: CD000011.
27. Senthilselvan A, Lawson JA, Rennie DC, Dosman JA. Regular use of corticosteroids and low use of short-acting beta2- agonists can reduce asthma hospitalization. Chest 2005;127: 1242-51. (Pubitemid 46224287)
28. Stern L, Berman J, Lumry W, et al. Medication compliance and disease exacerbation in patients with asthma: A retrospective study of managed care data. Ann Allergy Asthma Immunol 2006;97:402-8.
29. Molimard M, Le Gros V. Impact of patient-related factors on asthma control. J Asthma 2008;45:109-13. (Pubitemid 351416961)
30. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114: 1288-93. (Pubitemid 39575880)
31. American Lung Association. CFC-free Inhalers: Time to Make the Switch. Available from: Http://www.lungusa. org/site/c.dvLUK9O0E/b.2222599/. [Accessed March 4, 2009].
32. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78. (Pubitemid 38580764)
33. Miller MK, Johnson C, Miller DP, et al. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005;116:990-5. (Pubitemid 41571777)